Navigation Links
Cytopia's CYT387 Receives FDA Clearance to Start US Clinical Trials
Date:9/3/2009

MELBOURNE, Australia, Sept. 3 /PRNewswire/ -- Cytopia Limited's (ASX: CYT) Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders. The company's IND application is now active and Cytopia is able to proceed with clinical trials for CYT387 in the United States.

CYT387 will be the second of Cytopia's compounds to enter clinical trials. The company's anti-cancer vascular-disrupting agent CYT997 is already in Phase II studies in Australia.

Hyperactivity of the JAK2 enzyme is known to cause a number of haematological conditions known as myeloproliferative disorders (MPDs). This group of diseases includes myelofibrosis, polycythemia vera and essential thrombocythemia. In addition, Cytopia has identified potential activity of CYT387 in a range of cancers which may substantially enlarge the value of this compound.

Dual JAK1/JAK2 inhibition is likely to increase the clinical benefit in these disease indications and broaden the therapeutic opportunities for CYT387. JAK kinase inhibitors with similar profiles are also being trialled in inflammatory diseases such as rheumatoid arthritis. CYT387 possesses optimized JAK1/JAK2 inhibition while minimising unwanted activity seen with other JAK2 inhibitors in clinical development.

Preparations for the company's initial Phase I/II trial of CYT387 in patients with myelofibrosis are currently being finalized. Myelofibrosis is a life-threatening scarring of the bone marrow. This study will be undertaken at the Mayo Clinic in Rochester Minnesota under the chairmanship of Dr. Ayalew Tefferi, a key opinion leader in MPD treatment. The company anticipates opening the study to enrolment in the fourth quarter of 2009. Further details of the study will be disclosed following site ethics co
'/>"/>

SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
2. Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy
3. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
4. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
5. Covance Receives Highest Level of Phase I Accreditation
6. Worlds First Cardiac Adult Stem Cell Patient Receives Infusion
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
9. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
10. USC Keck School of Medicines Dr. Alan Epstein Receives Prestigious National Cancer Institute RAID Award for Breakthrough IL-2 Molecule Therapeutic
11. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014   DaVita ... ), one of the nation,s largest and most ... DaVita University Academy – the company,s award-winning, leadership ... Nearly 2,000 DaVita teammates from around the globe ... DaVita University Academy is a two-day one-of-a-kind ...
(Date:10/16/2014)... MARLBOROUGH, Mass. , Oct. 16, 2014 ... received CE Mark approval for the ACCOLADE TM ... leads, ACCOLADE pacemakers are the first to enable ... Tesla and 3.0 Tesla systems. In addition, the Boston ... MRI options, allowing higher energy scan sequences, and featuring ...
(Date:10/16/2014)... 2014 The Parenteral Drug Association ... application of single-use, or disposable, systems in ... products with the publication of Technical ... Single-Use Systems in Pharmaceutical Manufacturing. ... systems (SUS) or single-use equipment, has the ...
Breaking Medicine Technology:DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 2Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 3Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 4Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 5PDA Offers Help in Applying Single-Use Systems to Bio/Pharma Operations 2
... 18, 2011 The U.S. Food and Drug Administration ... treat patients with acute lymphoblastic leukemia (ALL), who have ... derived asparaginase and pegaspargase chemotherapy drugs used to treat ... Acute lymphoblastic leukemia is a type of ...
... and OXFORD, England, Nov. 18, 2011   EUSA Pharma, a ... supportive care and critical care, today announced that ... approved its orphan drug ERWINAZE™ (asparaginase Erwinia ... leukemia (ALL) in patients with hypersensitivity to ...
Cached Medicine Technology:FDA Approves Erwinaze to Treat a Form of Leukemia 2FDA Approves Erwinaze to Treat a Form of Leukemia 3EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia 2EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia 3EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia 4
(Date:10/19/2014)... Having been working in the garment industry ... customer needs. According to James, one of the company’s top ... or with high-low skirts that add beauty to them. Chiffon ... LunaDress has unveiled its new selection of 2014 long prom ... brand new items are available in over 20 popular designs. ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many kinds ... designs of 2014 mother of the bride dresses ... offered with big discounts, up to 70% off. All ... enjoy this special offer. , Owing to the ... one of the leading brands in the global market. ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Visual ... program has just been released to the public ... online body building and fitness community. The commotion ... of DietsAndFitnessGuides.com's Vin Delmonico prompting an investigative review. ... of hitting what is commonly known as a ...
(Date:10/19/2014)... News) -- New stem cell-based research could improve understanding ... a new study suggests. Scientists used stem cells ... a lab dish. They then transplanted the organoids into ... according to the researchers. "This provides a new ... can cause intestinal failure, from genetic disorders appearing at ...
(Date:10/19/2014)... CHICAGO, OCTOBER 20, 2014 – The U.S. Government ... effectively treat Alzheimer,s disease by 2025. However, a ... says the research milestones in the U.S. Government,s ... broadened in scope, increased in scale, and adequately ... A series of proposals by the workgroup to ...
Breaking Medicine News(10 mins):Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
... on the Indian front has run into rough weather ... Parke-Davis (India). A local court in Hyderabad has ... city. ,The vacation court of the Ranga Reddy ... machinery of Parke-Davis (India) following a petition filed by ...
... has found a new treatment - Vedic vibration technology. ... Vedic Vibration Technology in subjects with arthritis,' revealed that scientists ... in 36 per cent of the patients treated and at ... cent cases. ,The study was recently conducted in Berlin ...
... certain cancers, hepatitis and multiple sclerosis with interferon therapy ... can seriously spoil its quality. Alpha interferon a ... depression. ,A new research now shows that the ... avoid this problem. Almost 50% of people on ...
... Bank, whose website (www.worldbank.org) declares "Our dream is a ... private hospital in Mumbai, India, a move which some ... assistance for projects that will mainly benefit the rich. ... state an International Development Association loan of $134m (89m), ...
... says that women with low risk pregnancies, who live in the ... during pregnancy to 3 - 6 times during pregnancy instead of ... ,However, these women are not more at risk than women ... baby, or have anemia during pregnancy, or spend longer in the ...
... Genetic variations in the HIV strains in Africa make it more ... to researchers. This however does not mean that these drugs will ... to latch on to the protease, which is an enzyme useful ... the drug attaches itself to the protease, then it is easier ...
Cached Medicine News:Health News:The World Bank funds private Hospital in India 2
... are available in 14 configurations including the ... Microgenics Antibody Technology, the SureStep MDMA (Ecstasy) ... immunoassay targeted to detect MDMA that has ... but no cross-reactivity to any isomer of ...
... Tests are available in 14 configurations including ... using Microgenics Antibody Technology, the SureStep™ MDMA ... care immunoassay targeted to detect MDMA that ... MDEA but no cross-reactivity to any isomer ...
AccuSign DOA Series tests include tests for Amphetamines, Barbituates, Benzodiazepines, Cocaine, Methadone, Methamphetamines, Nicotine (Cotinine), Opiates, Phencyclidine, THC, Tricyclic Antidepressan...
... The InstaCheck® multi-drug test device ... and easily. Negative results can ... as 3 minutes; positive results ... simple, one-time urine sample application ...
Medicine Products: